Skip to main content
Clinical Trials/NCT04665648
NCT04665648
Completed
Phase 4

Impact of Intravenous Administration of Nicorandil As Adjuncts to Reperfusion Treatment for Acute ST Segment Elevation Myocardial Infarction: a Multi-center Randomized Controlled Trial

Fudan University1 site in 1 country1,500 target enrollmentJune 1, 2021

Overview

Phase
Phase 4
Intervention
Nicorandil
Conditions
ST Elevation Myocardial Infarction
Sponsor
Fudan University
Enrollment
1500
Locations
1
Primary Endpoint
Major adverse cardiac events
Status
Completed
Last Updated
last year

Overview

Brief Summary

The investigators evaluate the efficacy and safety of intravenous administration of nicorandil as adjuncts to reperfusion treatment in acute ST-segment elevation acute myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PCI).

Registry
clinicaltrials.gov
Start Date
June 1, 2021
End Date
December 31, 2024
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Ge Junbo

Director, Dept. of Cardiology, Zhongshan Hospital, Fudan University, Shanghai, China

Fudan University

Eligibility Criteria

Inclusion Criteria

  • 18-80 years;
  • acute ST-segment elevation myocardial infarction within 12 hours of symptom onset;

Exclusion Criteria

  • systolic blood pressure\<100mmHg;
  • cardiac shock;
  • aortic dissection;
  • history of myocardial infarction or percutaneous coronary intervention or coronary artery bypass grafting (\<6 month);
  • history of the treatment of nicorandil (\<6 month);
  • history of intravenous nitrates before percutaneous coronary intervention;
  • contraindicated or intolerable to nicorandil;
  • pregnant or lactation period;
  • patients with an estimated survival time of less than 1 year.

Arms & Interventions

Treatment arm

Patients who received intravenous nicorandil before and after reperfusion with primary percutaneous coronary intervention

Intervention: Nicorandil

Placebo arm

Patients who received intravenous placebo before and after reperfusion with primary primary percutaneous coronary intervention

Intervention: Placebo

Outcomes

Primary Outcomes

Major adverse cardiac events

Time Frame: 12 month after primary PCI

cardiac death, myocardial reinfarction, target vessel revascularization, unplanned hospitalization for heart failure

Secondary Outcomes

  • Rate fo complete ST-segment resolution(2 hours after primary PCI)
  • Unplanned hospitalization for heart failure(12 months after primary PCI)
  • Rate of slow re-flow/no-reflow(3 minutes after primary PCI)
  • Cardiac death(12 months after primary PCI)
  • Myocardial reinfarction(12 months after primary PCI)
  • Target vessel revascularization(12 months after primary PCI)

Study Sites (1)

Loading locations...

Similar Trials